IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies

Provides a look at the new manufacturing facility in Huntsville, Alabama

Introduced as part of IMUNON's newly relaunched website

LAWRENCEVILLE, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced the release of an enterprise video that highlights the company’s mission, vision, values, breakthroughs and technologies.

The video, which can be viewed on IMUNON's newly relaunched website (www.IMUNON.com), provides an overview of the company and its mission to develop innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases. It was filmed in large part during the unveiling of IMUNON’s new current Good Manufacturing Practices (cGMP) facility in the Huntsville, Alabama campus of the AlphaHudson Institute for Biotechnology. The facility is intended to enhance IMUNON’s control over the quantities and costs of manufacturing non-viral DNA-based materials used in its research and development activities. The video continues with a discussion of IMUNON’s vision for the future of immunotherapy, its values of innovation, collaboration and patient-centricity, and its recent breakthroughs in the development of DNA-based vaccines and therapeutics.

“We are proud to release our first-ever enterprise video to share our story,” said Dr. Corinne Le Goff, president and chief executive officer of IMUNON. “It provides an excellent overview of our company as well as our vision for the future of immunotherapy. We believe that this video will help to raise awareness of our work and the potential of DNA-based immunotherapy to address some of the most challenging diseases facing humanity.”

The video features interviews with several IMUNON scientists and executives who discuss the company’s technology and its potential to revolutionize the treatment of disease.

“We believe that DNA-based immunotherapy has the potential to be a game-changer in the fight against disease,” said Khursheed Anwer, Ph.D., executive vice president and chief scientific officer of IMUNON. “Our non-viral technology has the ability to generate powerful and durable immune responses, and we are excited to explore its many benefits with an initial focus on oncology and infectious diseases.”